Zevra Therapeutics (ZVRA) News Today $8.62 -0.41 (-4.54%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period FY2026 Earnings Estimate for ZVRA Issued By William BlairNovember 17 at 3:53 AM | americanbankingnews.comCanaccord Genuity Group Cuts Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $23.00November 17 at 3:17 AM | americanbankingnews.comRoth Capital Has Pessimistic Outlook of ZVRA FY2024 EarningsNovember 17 at 1:13 AM | americanbankingnews.comAnalysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter ReportNovember 16 at 12:55 PM | uk.finance.yahoo.comZevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy RatingNovember 16 at 7:54 AM | markets.businessinsider.comZevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy RatingNovember 16 at 7:54 AM | markets.businessinsider.comSimplify Asset Management Inc. Makes New $833,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Simplify Asset Management Inc. purchased a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 120,000 shares of theNovember 15 at 11:17 AM | marketbeat.comResearch Analysts Set Expectations for ZVRA FY2026 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, November 13th. William Blair analyst S. Corwin expects that the company will post earninNovember 15 at 8:50 AM | marketbeat.comResearch Analysts Set Expectations for ZVRA FY2024 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at Roth Capital lowered their FY2024 earnings estimates for Zevra Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff now anticipates that the companyNovember 15 at 6:03 AM | marketbeat.comShort Interest in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Drops By 21.2%Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) was the target of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 3,940,000 shares, a decrease of 21.2% from the October 15th total of 5,000,000 shares. Currently, 7.5% of the company's stock are sold short. Based on an average daily volume of 851,000 shares, the days-to-cover ratio is presently 4.6 days.November 15 at 4:42 AM | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Given New $23.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group lowered their target price on Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday.November 14 at 11:33 AM | marketbeat.comResearch Analysts Set Expectations for ZVRA Q4 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at Roth Capital issued their Q4 2025 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued to investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff anticipatesNovember 14 at 9:36 AM | marketbeat.comZevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comZevra Therapeutics: Strong MIPLYFFA Launch and Strategic Investments Justify Buy Rating Despite OLPRUVA ChallengesNovember 13, 2024 | markets.businessinsider.comZevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...November 13, 2024 | finance.yahoo.comJanney Montgomery Scott LLC Has $2.12 Million Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Janney Montgomery Scott LLC decreased its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 29.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 305,069 shares of the company's stNovember 13, 2024 | marketbeat.comZevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate UpdatesNovember 13, 2024 | markets.businessinsider.comWilliam Blair pharmaceuticals analysts hold analyst/industry conference callNovember 12, 2024 | markets.businessinsider.comZevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 12, 2024 | finance.yahoo.comZevra Therapeutics Q3 2024 Earnings PreviewNovember 12, 2024 | msn.comBrokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $20.83November 12, 2024 | americanbankingnews.comZevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual MeetingNovember 11, 2024 | globenewswire.comZevra Therapeutics (ZVRA) Scheduled to Post Quarterly Earnings on TuesdayNovember 11, 2024 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of "Buy" from AnalystsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has received a consensus recommendation of "Buy" from the eight ratings firms that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buyNovember 7, 2024 | marketbeat.comZevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13November 6, 2024 | globenewswire.comZevra Therapeutics (ZVRA) to Release Earnings on TuesdayZevra Therapeutics (NASDAQ:ZVRA) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643172)November 5, 2024 | marketbeat.comZevra Therapeutics (ZVRA) to Release Quarterly Earnings on TuesdayZevra Therapeutics (NASDAQ:ZVRA) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643172)November 5, 2024 | marketbeat.comZevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024October 31, 2024 | globenewswire.comSanctuary Advisors LLC Makes New $474,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Sanctuary Advisors LLC acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 104,924 shares of the company's stock, valued at approximatelyOctober 17, 2024 | marketbeat.comBuy Rating Affirmed for Zevra Therapeutics Based on Strong NPV and Future Market PotentialOctober 14, 2024 | markets.businessinsider.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by BrokeragesZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has earned an average recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buyOctober 13, 2024 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Given Overweight Rating at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Zevra Therapeutics in a research note on Friday.October 11, 2024 | marketbeat.comZevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...October 10, 2024 | finance.yahoo.comZevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCOctober 10, 2024 | globenewswire.comGuggenheim Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy RecommendationOctober 8, 2024 | msn.comHC Wainwright Comments on Zevra Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - HC Wainwright dropped their Q3 2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research report issued to clients and investors on Monday, September 30th. HC Wainwright analyst O. Livnat now anticipates that the cOctober 2, 2024 | marketbeat.comFY2026 Earnings Forecast for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Issued By HC WainwrightZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at HC Wainwright cut their FY2026 earnings estimates for Zevra Therapeutics in a note issued to investors on Monday, September 30th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of $0.59October 1, 2024 | marketbeat.comBuy Rating Reaffirmed for Zevra Therapeutics Amidst Unjustified Market Reaction and Strong Drug ProspectsOctober 1, 2024 | markets.businessinsider.comZevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Monday.September 30, 2024 | marketbeat.comRoth Capital Weighs in on Zevra Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:ZVRA)Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Roth Capital reduced their FY2024 earnings per share estimates for Zevra Therapeutics in a research note issued on Tuesday, September 24th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($1.57) fSeptember 26, 2024 | marketbeat.comInvestors in Zevra Therapeutics (NASDAQ:ZVRA) have seen decent returns of 67% over the past yearSeptember 25, 2024 | finance.yahoo.comZevra Therapeutics (NASDAQ:ZVRA) PT Raised to $21.00Roth Mkm lifted their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Tuesday.September 24, 2024 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated by Analysts at JMP SecuritiesJMP Securities began coverage on shares of Zevra Therapeutics in a research report on Tuesday. They issued an "outperform" rating and a $17.00 price objective for the company.September 24, 2024 | marketbeat.comZevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024September 24, 2024 | globenewswire.comFDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C -- 2nd UpdateSeptember 21, 2024 | marketwatch.comFDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New PeaksSeptember 21, 2024 | markets.businessinsider.comZevra Therapeutics (NASDAQ:ZVRA) PT Raised to $20.00HC Wainwright lifted their price objective on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Friday.September 20, 2024 | marketbeat.comZevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type CSeptember 20, 2024 | globenewswire.comUS FDA approves Zevra's genetic disorder treatmentSeptember 20, 2024 | reuters.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given a consensus recommendation of "Buy" by the six brokerages that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the coSeptember 18, 2024 | marketbeat.com Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Why buying gold might be a mistake (Ad)Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level. If you're interested, check out the recording here while the link's still up. ZVRA Media Mentions By Week ZVRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVRA News Sentiment▼0.470.56▲Average Medical News Sentiment ZVRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVRA Articles This Week▼363▲ZVRA Articles Average Week Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Galapagos News Intellia Therapeutics News Immunocore News Kiniksa Pharmaceuticals News Xencor News Ocular Therapeutix News ARS Pharmaceuticals News Day One Biopharmaceuticals News Evotec News Praxis Precision Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVRA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVRA Stock Alerts